Cathy Eng, MD
A number of unmet needs have been addressed in the gastrointestinal (GI) cancer space, but there are still large patient populations who rely on traditional treatment regimens, said Cathy Eng, MD.
For example, in colorectal cancer (CRC), immunotherapy has had a significant impact in patients who have microsatellite instability-high (MSI-H) tumors. However, the vast majority of patients who are microsatellite stable (MSS) are still treated with chemotherapy, noted Eng, a professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center.
... to read the full story